FDA pharmacologic class
Bispecific CD20-directed CD3 T Cell Engager
2 medicines are in FDA's class of bispecific cd20-directed cd3 t cell engagers: epcoritamab (Epkinly) and glofitamab (Columvi). 0 of the 2 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are bispecific cd20-directed cd3 t cell engager?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Epcoritamab | Epkinly | none listed | n/a | Yes | No current entry | 0 |
| Glofitamab | Columvi | none listed | n/a | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)